The event will provide the full 3-year data from all cohorts of the open label Phase 1 study of MeiraGTx’s AAV-hAQP1 for the treatment of persistent grade 2/3 moderate to severe radiation-induced xerostomia (RIX), 3 or more years after curative radiation treatment for head and neck cancer.

Dr. Michael Brennan, Atrium Health Carolinas Medical Center, and Mr. David Owens, University Hospital of Wales will discuss the unmet need and current treatment landscape.

Xerostomia (dry mouth) is a condition in which a person’s salivary glands do not produce enough saliva. Symptoms of persistent Grade 2/3 moderate to severe RIX include difficulty eating, swallowing and chewing, resulting in poor nutrition and potentially a feeding tube. Speaking and exercise can be impaired, constant oral pain and infection and uncontrollable dental caries are also consequences of persistent RIX. AAV-hAQP1 is an investigational genetic medicine that is designed to improve xerostomia by increasing water flow in salivary glands damaged by radiation therapy for head and neck cancer.

In March 2026, the FDA granted AAV-hAQP1 Breakthrough Therapy Designation. AAV-hAQP1 has also received Regenerative Medicine Advanced Therapy (RMAT) designation and Orphan Disease Designation (ODD).

A live question and answer session will follow the formal presentations.